Research programme: proto oncogene proteins c-akt inhibitors - DeveloGen
Latest Information Update: 24 Sep 2010
At a glance
- Originator DeveloGen
- Class Small molecules
- Mechanism of Action Proto oncogene protein c-akt inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 02 Sep 2010 DeveloGen has been acquired by Evotec AG
- 21 Jun 2007 Teva Pharmaceutical Industries granted an exclusive worldwide license to DeveloGen's protein kinase B technology for the treatment of cancer
- 14 Jun 2004 Peptor has been acquired by, and merged into, DeveloGen